Medical Cannabis Oils: Formulation, Stability and Quality

Overview

Cannabis oils appear simple but require control of extract composition, carrier oil, concentration, homogeneity, oxidation, packaging and dosing performance. Product quality depends on much more than reporting total CBD and THC.

Formulation design

Formulation design for medical cannabis oils starts with the target dose per delivered drop or millilitre, since this determines extract concentration, carrier ratio and the precision required from the filling process. The formulation must account for cannabinoid solubility limits in the chosen carrier — exceeding these can cause crystallisation or separation on storage, which is a common and preventable formulation failure.

Excipient selection is not incidental to quality: carrier oil purity, any co-solvents or emulsifiers, and antioxidant additives all interact with the extract and can affect both stability and patient tolerability. A robust formulation specification defines acceptable ranges for each excipient, not just the labelled cannabinoid content.

Extract and carrier controls

Carrier oil selection determines both stability and bioavailability. MCT oil, sunflower oil and other lipid carriers differ in viscosity, oxidative stability and their ability to solubilise cannabinoids without precipitation on storage. The extract itself must be characterised for cannabinoid ratio, terpene retention and residual solvent before formulation, since carrier compatibility depends on the extract's own composition, not on cannabis as a generic category.

Formulation must also account for delivered-dose accuracy: dropper calibration, oil viscosity and any settling of suspended extract between shakes all affect whether the labelled concentration matches what the patient actually receives. Stability testing should confirm cannabinoid content and appearance remain within specification for the full intended shelf life under realistic storage conditions.

Homogeneity and dosing

Manufacturing control begins with a clear material specification and traceability. Critical variables may include cultivar, harvest timing, drying conditions, extraction parameters, solvent exposure, temperature, oxygen, light and hold times. The relevant variables should be identified through risk assessment and linked to measurable quality attributes.

Equipment and facilities should be appropriate for the operation, cleanable, maintained and qualified to the extent justified by risk. Where processing crosses from agricultural handling into pharmaceutical manufacture, responsibilities and documentation at the GACP–GMP interface must be explicit.

Oxidation and stability

Analytical control of medical cannabis oils requires suitable sampling, qualified instruments, appropriate reference standards and methods capable of separating the analytes that matter. Results can be misleading when acidic and neutral cannabinoids are combined inconsistently, moisture correction is unclear, matrix effects are ignored or calculations are not standardised.

A specification should be clinically and process relevant rather than a list of every measurable parameter. Identity, assay, related substances or degradation indicators, microbiological quality, contaminants and physical attributes should be selected according to the product and route of administration.

Packaging and specification

Lifecycle control extends beyond initial release. Stability studies should represent the marketed packaging and storage conditions, while deviations, out-of-trend results and complaints should feed back into the risk assessment. Changes to cultivar, supplier, equipment, method, packaging or process parameters require impact assessment before implementation.

The strongest approach is conservative and transparent: define the product, control variability, validate the measurements, communicate uncertainty and avoid claims that outrun the evidence. This is the difference between a novelty-led product and a pharmaceutical-quality product.

Implementation checklist

Before scaling a cannabis oil formulation, confirm the extract supplier can consistently deliver the required cannabinoid ratio and terpene profile, and that the carrier oil has been tested for compatibility at the target concentration. Verify dropper or dosing device calibration against actual fill volume, not just nominal specification. Check that the stability protocol covers the full intended shelf life under realistic storage conditions, and that packaging has been tested for compatibility with the specific oil formulation, not assumed from generic container data.

Control framework

Practical sequence

References and primary guidance

1. European Commission, EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice.
2. ICH Q9(R1), Quality Risk Management.
3. ICH Q10, Pharmaceutical Quality System.
4. European Pharmacopoeia, applicable general monographs and analytical chapters.

References should be checked against the current consolidated legislation, pharmacopoeial edition and competent-authority guidance before operational use.

Frequently asked questions

Related ECI reading

Educational content only. This page does not constitute medical, legal or regulatory advice.